What do primary care patients think about generic drugs?

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 10, 2005, Pages 472-479

  Himmel, W ^a   Simmenroth Nayda, A ^a   Niebling, W ^b   Ledig, T ^c   Jansen, R D ^c   Kochen, M M ^a   Gleiter, C H ^d   Hummers Pradier, E ^a,e  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c General Practice Health Center   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cost effectiveness; Family practice; Generic drugs; Information on drug therapy; Prescriptions

Indexed keywords

GENERIC DRUG;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG COST; EDUCATION; GENERAL PRACTITIONER; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PATIENT SATISFACTION; PRESCRIPTION; PRIMARY MEDICAL CARE; QUESTIONNAIRE;

EID: 26844478378     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43472     Document Type: Article

References (33)

1. Ascione FJ, Kirking DM, Gaither CA, Welage LS 2001 Historical overview of generic medication policy. J Am Pharm Assoc (Wash) 41: 567-577
2. Avery AJ Rodgers S, Heron T, Crombie R, Whynes D, Pringle M et al 2000 A prescription for improvement? An observational study to identify how general practices vary in their growth in prescribing costs. BMJ 321: 276-281
3. Bae JP 1997 Drug patent expirations and the speed of generic entry. Health Serv Res 32: 87-101
4. Banahan BF 3rd, Kolassa EM 1997 A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med 157: 2080-2088
5. Barsky AJ, Saintfort R, Rogers MP, Borus JF 2002 Non-specific medication side effects and the nocebo phenomenon. JAMA 287: 622-627
6. Brennan TA, Lee TH 2004 Allergic to generics. Ann Intern Med 141: 126-130
7. de Joncheere K, Rietveld AH, Huttin C 2002 Experiences with generics. Int J Risk Safety Med 15: 101-109
8. Detlefsen K, Himmel W, Simmenroth-Nayda A, Hummers-Pradier E, Kochen MM 2001 What do patients think about generic substitution? (In German). 35th Congress of the German Society of General Practice and Family Medicine (DEGAM), September 2001. Z Allgemeinmed 77: 19 (Congress Abstracts, 41)
9. Dowell JS, Snadden D, Dunbar JA 1995 Changing to generic formulary: how one fundholding practice reduced prescribing costs. BMJ 310: 505-508
10. Ganther JM, Kreling DH 2000 Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc (Wash) 40: 378-383
11. Gleiter CH, Gundert-Remy U 1994 Bioinequivalence and drug toxicity. How great is the problem and what can be done? Drug Saf 11: 1-6
12. Gleiter CH, Klotz U, Kuhlmann J, Blume, H, Stanislaus F, Harder S et al 1998 When are bioavailability studies required? J Clin Pharmacol 38: 904-911
13. Heffler S, Levit K, Smith S, Smith C, Cowan C, Lazenby H et al 2003 Health spending projections for 2002-2012. Health Aff (Millwood) 22: W3 54-65
14. Hellerstein JK 1998 The importance of the physician in the generic versus trade-name prescription decision. Rand J Econ 29: 108-136
15. Horn SD, Sharkey PD, Tracy DM, Horn CE, James B, Goodwin F 1996 Intendend and unintendend consequences of HMO cost-containment strategies: results from the Managed Care Outcomes Project. Am J Manag Care 2: 253-564
16. Keith LG, Oleszczuk JJ, Stika CS, Stine S 1998 Generics: what's in a name? Int J Fertil Womens Med 43: 139-149
17. Kravitz RL, Romano PS 1996 Managed care cost containment and the law of unintended consequences (editorial). Am J Manage Care 2: 323-324
18. Lemye R 2000 Generic drugs (in French). Rev Med Brux 21: A273-275
19. Liberman A, Rubinstein J 2002 Health care reform and the pharmaceutical industry: crucial decisions are expected. Health Care Manag 20: 22-32
20. Lundin D 2000 Moral hazard in physician prescription behavior. J Health Econ 19: 639-662
21. McGettigan P McManus J, O'Shea B, Chan R, Feely J 1997 Low rate of generic prescribing in the Republic of Ireland compared to England and Northern Ireland: prescribers' concerns. Ir Med J 90: 146-147
22. Meredith PA 1996 Generic drugs. Therapeutic equivalence. Drug Saf 4: 233-242
23. Mott DA, Kreling DH 1998 The association of insurance type with costs of dispensed drugs. Inquiry 35: 23-35
24. Mott DA, Cline RR 2002 Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care 40: 662-674
25. Nink K, Schröder H 2004 Economic aspects of the German pharmaceutical market 2003 (in German). In: Schwabe U, Paffrath D (eds) Arzneiverordnungs-Report (Drug Prescription Report). Springer, Berlin, pp 137-175
26. Olson-Garewal 2001 Making sense of outpatient pharmacy management. How to control pharmacy costs while delivering quality care. Postgrad Med 110: 7-10
27. Pedulka M, Krautkramer K, Amerson D, Phillips B, Dolinsky D 1989 Consumers' attitude towards generic drugs. J Pharm Mark Manage 4: 93-104
28. Rietveld AH, Haaijer-Ruskamp FM 2002 Policy options for cost containment of pharmaceuticals. Int J Risk Safety Med 15: 29-54
29. SAS Institute Inc 1999 SAS/STAT. User's Guide Version 8. SAS Institute Inc, Cary, NC
30. Schwabe U 2004 Drug prescriptions in 2003 (in German). In: Schwabe U, Paffrath D (eds) Arzneiverordnungs-Report (Drug Prescription Report). Springer, Berlin, pp 1-36
31. Suh DC 1999 Trends of generic substitution in community pharmacies. Pharm World Sci 21: 260-265
32. Vallès JA 2003 A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice Health Policy 65: 269-275
33. Welage LS, Kirking DM, Ascione FJ, Gaither CA 2001 Understanding the scientific issues embedded in the generic drug approval process. J Am Pharm Assoc (Wash) 41: 856-860